Nobabelle Cala (Ethinylestradiol, Gestodene)

• Nobabelle Cala, a combined oral contraceptive, is used to manage reproductive health by providing hormonal regulation.
• Prevention of pregnancy: provides reliable contraception for women of child‑bearing potential.
• Menstrual cycle regulation: helps establish predictable monthly bleeding patterns.
• Acne improvement: reduces androgen‑driven skin lesions in some users.
• Management of endometriosis symptoms: suppresses ovarian hormone production to alleviate pelvic pain.

• Ethinylestradiol and gestodene act together to suppress the hypothalamic‑pituitary‑ovarian axis, inhibiting the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH). This prevents follicular development and ovulation. The estrogen component stabilises the endometrium, while the progestogen thickens cervical mucus and induces endometrial changes that make implantation unlikely.

Nobabelle Cala may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects

• Nausea or mild gastrointestinal upset.
• Breast tenderness or enlargement.
• Headache or migraine.
• Weight gain or fluid retention.
• Mood swings or irritability.
• Breakthrough or spotting bleeding.

Serious or Rare Side Effects

• Venous thromboembolism (deep‑vein thrombosis, pulmonary embolism).
• Arterial thrombosis (stroke, myocardial infarction).
• Severe hypertension or hypertensive crisis.
• Liver adenoma or other hepatic tumors.
• Anaphylactic or severe allergic reactions.
• Visual disturbances or sudden loss of vision.

• Before prescribing Nobabelle Cala, clinicians should consider several precautionary measures to ensure safe use.
• Smoking: avoid use in women over 35 who smoke, due to increased thrombotic risk.
• History of thromboembolism: contraindicated in patients with prior venous or arterial clotting events.
• Pregnancy: discontinue immediately if pregnancy is confirmed.
• Liver disease: use with caution in active liver disease or hepatic tumors.
• Hypertension: monitor blood pressure regularly in patients with elevated readings.
• Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture.

Nobabelle Cala can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin) that reduce hormonal levels.
• Rifampicin or other potent inducers of CYP3A4, which may diminish contraceptive effect.
• St. John's wort, a herbal inducer that can lead to contraceptive failure.

Moderate Interactions (Monitor Closely)

• Certain antifungals (e.g., ketoconazole) that may increase hormone concentrations.
• Macrolide antibiotics (e.g., erythromycin) that can modestly raise plasma levels.
• Lithium, where hormonal changes may affect lithium clearance and toxicity risk.